Moriyama Noriaki, Sugiyama Yoichi, Miyashita Hirokazu, Yokoyama Hiroaki, Yamaguchi Masashi, Ochiai Tomoki, Shishido Koki, Jalanko Mikko, Yamanaka Futoshi, Vähäsilta Tommi, Laine Mika, Saito Shigeru
Cardiology and Catheterization Laboratories, Shonan Kamakura General Hospital, Kamakura, Japan.
Cardiology and Catheterization Laboratories, Shonan Kamakura General Hospital, Kamakura, Japan; Heart and Lung Center, Helsinki University and Helsinki University Central Hospital, Helsinki, Finland.
Am J Cardiol. 2023 Nov 15;207:140-149. doi: 10.1016/j.amjcard.2023.08.104. Epub 2023 Sep 20.
The optimal percent oversizing (%OS) using the SAPIEN3 Ultra (S3U) weighing the incidence of paravalvular regurgitation (PVR) ≥ mild against the risk of conduction disturbance (CD) is not known. This study sought to define an optimal extent of the annulus area %OS suitable for transcatheter aortic valve implantation with the S3U compared with the SAPIEN3 (S3). A total of 350 patients with the S3U were compared with 606 patients with the S3. Patients were categorized depending on the degree of %OS. PVR ≥ mild was observed in 8.9% of patients with the S3U and in 21.8% of those with the S3 (p <0.001). The S3U demonstrated a sustainably lower incidence of PVR ≥ mild than the S3 in any extent of %OS. There was an inverse proportional relation between the extent of %OS and frequency of PVR ≥ mild in the S3, whereas the S3U group provided little change. The incidences of PVR ≥ mild were steady >5%OS in the S3 (5% to 10%OS: 13.3%, and >10%OS: 12.1%) and >0%OS in the S3U (0% to 5%OS: 5.9%, 5% to 10%OS: 6.0%, and >10%OS: 6.1%). An increasing %OS was independently associated with the occurrence of CD (<0%OS: 9.8%, 0% to 5%OS: 13.1%, 5% to 10%OS: 16.6%, and >10%OS: 19.2%, p = 0.012). The incidence of PVR ≥ mild and/or CD was the lowest (10.1%) in the 0% to 5%OS in patients with the S3U. In conclusion, the HomoSAPIEN2 study suggests that the S3U tolerates a lesser degree of %OS for mitigating PVR ≥ mild than the S3. Minimal %OS, ranging from 0% to 5%, may be optimal for the S3U with balancing the risk of PVR and CD. Trial Identifier: UMIN000040413/URL: https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000046115.
使用SAPIEN3 Ultra(S3U)时,权衡中重度瓣周反流(PVR)发生率与传导障碍(CD)风险的最佳过大尺寸百分比(%OS)尚不清楚。本研究旨在确定与SAPIEN3(S3)相比,适合使用S3U进行经导管主动脉瓣植入的瓣环面积%OS的最佳范围。共对350例使用S3U的患者与606例使用S3的患者进行了比较。根据%OS的程度对患者进行分类。在使用S3U的患者中,8.9%观察到中重度PVR,而使用S3的患者中这一比例为21.8%(p<0.001)。在任何%OS范围内,S3U中重度PVR的发生率均持续低于S3。在S3中,%OS程度与中重度PVR的频率呈反比关系,而S3U组变化不大。在S3中,中重度PVR的发生率在>5%OS时保持稳定(5%至10%OS:13.3%,>10%OS:12.1%),在S3U中>0%OS时保持稳定(0%至5%OS:5.9%,5%至10%OS:6.0%,>10%OS:6.1%)。%OS增加与CD的发生独立相关(<0%OS:9.8%,0%至5%OS:13.1%,5%至10%OS:16.6%,>10%OS:19.2%,p=0.012)。在使用S3U的患者中,0%至5%OS时中重度PVR和/或CD的发生率最低(10.1%)。总之,HomoSAPIEN2研究表明,与S3相比,S3U在减轻中重度PVR方面能耐受更低程度的%OS。对于S3U来说,0%至5%的最小%OS范围在平衡PVR和CD风险方面可能是最佳的。试验标识符:UMIN000040413/网址:https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000046115 。